Free Trial
OTCMKTS:BGMD

BG Medicine (BGMD) Stock Price, News & Analysis

BG Medicine logo

About BG Medicine Stock (OTCMKTS:BGMD)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
195,000 shs
Average Volume
2,500 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive BGMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BG Medicine and its competitors with MarketBeat's FREE daily newsletter.

BGMD Stock News Headlines

Modernizing Medicine
The #1 Coin for November 2024
Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…
Medicine Through Time
BGMD - BG Medicine, Inc.
Jiangsu Hengrui Medicine
Why BG Medicine (BGMD) Stock Is Plunging Today
See More Headlines

BGMD Stock Analysis - Frequently Asked Questions

BG Medicine, Inc. (OTCMKTS:BGMD) released its quarterly earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) EPS for the quarter. The medical research company earned $334 million during the quarter, compared to analyst estimates of $695 million.

Shares of BGMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that BG Medicine investors own include Aeterna Zentaris (AEZS), Glu Mobile (GLUU), Blue Ridge Mountain Resources (MHRCQ), ARCA biopharma (ABIO), Athersys (ATHX), Bristol-Myers Squibb (BMY) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/17/2015
Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Life Sciences Tools & Services
Current Symbol
OTCMKTS:BGMD
Previous Symbol
NASDAQ:BGMD
CUSIP
08861T10
Employees
5
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.63
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (OTCMKTS:BGMD) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners